Trial Profile
An Open-label(Part1), Single Arm(Part1), Randomized(Part2), Double-blind(Part2), Active-controlled(Part2), Phase III Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GC 3110A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GC Pharma; Green Cross
- 26 Mar 2018 Primary endpoint (The proportion of subjects who achieved seroconversion) has been met, according to results published in the Journal of Korean Medical Science.
- 26 Mar 2018 Primary endpoint (The proportion of subjects who achieved seroprotection) has been met, according to results published in the Journal of Korean Medical Science.
- 26 Mar 2018 Results (n=543) assessing immunogenicity and safety of an egg-cultivated QIV in healthy Korean children and adolescents, were published in the Journal of Korean Medical Science.